LIXT
LIXTE BIOTECHNOLOGY HOLDINGS, INC.
$6.19
-14.62%
$93.0M
No data for this timeframe.
Vol
Market Cap$93.0M
Cap SizeMicro Cap
Inst. Holders6 funds
Inst. Value$772.0K
Inst. Activity2 buys / 1 sells
SEC Reports6
Press Releases1
Recent Activity
Jun 4, 2026
SEC
Lixte Biotechnology closed a registered direct offering raising approximately $16.6 million in gross proceeds through th
8-K — Impact 6/10
Jun 4, 2026
SEC
Lixte Biotechnology is raising approximately $16.6 million in gross proceeds through a registered direct offering of 2,3
424B5 — Impact 6/10
Jun 1, 2026
SEC
LIXTE Biotechnology announced a strategic transformation into an AI energy infrastructure equipment & services platform,
8-K — Impact 6/10
May 29, 2026
Insider
Porter Stuart D was granted 25,000 shares
Director
Apr 15, 2026
Insider
Holloway Michael Andrew was granted 25,000 shares
Director
Apr 15, 2026
Insider
Sawyer Jason David disposed of 25,000 shares
Director
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
107,500 shares ($422.5K)
Inst.
VANGUARD GROUP INC — ADD
74,944 shares ($294.5K)
Latest Reports
BULLISH
Press
7/10
LIXTE Biotechnology (LIXT) announced a definitive agreement to acquire 100% of NOMAD Transportable Power Systems, a lead
Jun 12, 2026
BEARISH
8-K
6/10
Lixte Biotechnology closed a registered direct offering raising approximately $16.6 million in gross proceeds through th
Jun 4, 2026
BEARISH
424B5
6/10
Lixte Biotechnology is raising approximately $16.6 million in gross proceeds through a registered direct offering of 2,3
Jun 4, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | $285.5K | ADD |
| CITADEL ADVISORS LLC | $173.6K | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $151.9K | — |
| VANGUARD FIDUCIARY TRUST CO | $107.6K | — |
| STATE STREET CORP | $53.4K | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 29, 2026 | Porter Stuart | A | $0.00 |
| Apr 15, 2026 | Holloway Michael | A | $0.00 |
| Apr 15, 2026 | Sawyer Jason | D | $0.00 |
| Apr 15, 2026 | Sawyer Jason | A | $0.00 |
| Apr 15, 2026 | Primus Guy | A | $0.00 |
6 institutional holders with $772.0K total value (262,812 shares) as of 2026-Q1. Top holders: RENAISSANCE, CITADEL, VANGUARD.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RENAISSANCE TECHNOLOGIES LLC | 93,000 | $285.5K | 37.0% | ADD +47.0% |
| 2 | CITADEL ADVISORS LLC | 56,557 | $173.6K | 22.5% | — |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 49,479 | $151.9K | 19.7% | — |
| 4 | VANGUARD FIDUCIARY TRUST CO | 35,034 | $107.6K | 13.9% | — |
| 5 | STATE STREET CORP | 17,396 | $53.4K | 6.9% | — |
| 6 | HRT FINANCIAL LP | 11,346 | $34.00 | 0.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 73,150 | 107,500 | +47.0% | $422.5K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 48,533 | 74,944 | +54.4% | $294.5K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | TRIM | 138 | 52 | -62.3% | $205.00 | 2025-Q4 |
| UBS Group AG | DOUBLED | 1,112 | 16,747 | +1406.0% | $84.2K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 8,291 | 1,112 | -86.6% | $1.0K | 2025-Q2 |
| UBS Group AG | DOUBLED | 1,956 | 8,291 | +323.9% | $10.0K | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | ADD | 16 | 21 | +31.3% | $25.00 | 2025-Q1 |
| UBS Group AG | DOUBLED | 367 | 1,956 | +433.0% | $4.0K | 2024-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 309 | 16 | -94.8% | $30.00 | 2024-Q3 |
7 unique insiders with 13 transactions. Net insider value: $0.00 ($0.00 bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 29, 2026 | Porter Stuart D | Director | AWARD | 25,000 | — | — |
| Apr 15, 2026 | Holloway Michael Andrew | Director | AWARD | 25,000 | — | — |
| Apr 15, 2026 | Sawyer Jason David | Director | D | 25,000 | — | — |
| Apr 15, 2026 | Sawyer Jason David | Director | AWARD | 25,000 | — | — |
| Apr 15, 2026 | Primus Guy Warren | Director | AWARD | 25,000 | — | — |
| Apr 15, 2026 | Primus Guy Warren | Director | D | 25,000 | — | — |
| Apr 15, 2026 | Holloway Michael Andrew | Director | D | 25,000 | — | — |
| Apr 15, 2026 | Stazzone Peter | Chief Financial Officer | AWARD | 50,000 | — | — |
| Apr 15, 2026 | Stazzone Peter | Chief Financial Officer | D | 50,000 | — | — |
| Apr 15, 2026 | Felix Lourdes | Director | AWARD | 25,000 | — | — |
| Apr 15, 2026 | Pursglove Geordan Garrett | CEO and Chairman of the Board | AWARD | 350,000 | — | — |
| Apr 15, 2026 | Pursglove Geordan Garrett | CEO and Chairman of the Board | D | 350,000 | — | — |
| Apr 15, 2026 | Felix Lourdes | Director | D | 25,000 | — | — |
6 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 3 neutral. Avg impact: 4.8/10.
BEARISH
8-K
6/10
Lixte Biotechnology closed a registered direct offering raising approximately $16.6 million in gross
Jun 4, 2026
BEARISH
424B5
6/10
Lixte Biotechnology is raising approximately $16.6 million in gross proceeds through a registered di
Jun 4, 2026
BULLISH
8-K
6/10
LIXTE Biotechnology announced a strategic transformation into an AI energy infrastructure equipment
Jun 1, 2026
NEUTRAL
PRESS-RELEASE
3/10
Lixte Biotechnology filed its Q1 2026 10-Q, reporting an EPS of -$0.27 with no consensus estimate av
May 14, 2026
NEUTRAL
8-K
3/10
Lixte Biotechnology Holdings issued restricted share units (RSUs) to its CEO, CFO, and directors in
Apr 17, 2026
NEUTRAL
PRESS-RELEASE
5/10
{
"summary": "Lixte Biotechnology announced interim results from a Phase 1b trial combining its PP
Apr 13, 2026
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 12, 2026
m_and_a
LIXTE Biotechnology to Acquire NOMAD Transportable Power Systems, the Market Leader in Mobile, Utility-Grade Battery Energy Storage Systems (BESS)
<p align="center"><i>Company to be Renamed NOMAD Power Solutions • First-to-Market with the Mobile, Utility-Grade 1 MW BESS • Addressing a Multi-Hundr
Jun 3, 2026
other
LIXTE Biotechnology Announces $16,566,027 Registered Direct Offering Priced at the Market Under Nasdaq Rules, Strengthening Balance Sheet for Next Phase of Strategic Growth
<p><b><i>Announcement Follows the Recent Appointment of Denham Capital Founder Stuart D. Porter — a Three-Decade Energy and Infrastructure Investor —
Jun 1, 2026
other
LIXTE Biotechnology Announces Strategic Transformation into AI Energy Infrastructure Equipment & Services; Stuart D. Porter, Founder of Denham Capital, to Join Board of Directors
<p><i>Bringing More Than Three Decades of Energy Investment Experience, Mr. Porter Has Helped Build a Global Power Infrastructure Portfolio, Strengthe
May 14, 2026
earnings
LIXTE Biotechnology Files First Quarter 2026 Quarterly Report on Form 10-Q; Provides Operational Progress Update
<p align="justify"><strong>BOCA RATON, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- </strong>LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”)
May 13, 2026
earnings_calendar
LIXT Q1 2026 Earnings Scheduled — 2026-05-13
May 11, 2026
earnings_calendar
LIXT Q1 2026 Earnings Scheduled — 2026-05-11
Apr 13, 2026
earnings
Favorable Results of Ovarian Cancer Study Presented at Annual Society of Gynecological Care Conference
<p align="center"><b> </b><b><i>-Trial Combines LIXTE’s LB-100 with Dostarlimab; Results Give Patients New Hope </i></b><br><b><i>for a Challenging Di
Mar 31, 2026
earnings
LIXTE Biotechnology Files 2025 Annual Report on Form 10K, Provides Operational Highlights of Transformative Year
<p align="justify"><b>BOCA RATON, Fla., March 31, 2026 (GLOBE NEWSWIRE) -- </b>LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq
Mar 23, 2026
earnings_calendar
LIXT Q4 2025 Earnings Scheduled — 2026-03-23